Wednesday, September 15, 2021 5:27:24 PM
The WAC ( acquisition cost ) to the wholesaler is roughly $143 a month isn't it .......so the $50 extra you were charged ( after using the coupon ...your net cost was $193 ) ...is some how split between Costco / GoodRx /AMRN
?
The $50 you paid over WAC was probably split between CostCo and GoodRx ...if both were involved .
The good part is that AMRN made a " wholesale " sale because without that coupon reducing your cost above WAC to only $50 ...you may not have bt Vascepa .
Theres a whole field of economics on price/ demand flexibility curves that the 3 players ( Costco / GoodRx/ AMRN are involved in here .
Re V card and insurance getting you to $9 a month
If the WAC is around $143 a month ....to get you to $9 a month AMRN is definitely rebating ( purchase discount ) some $ to you to get your purchase ...unless you have one outrageously good ( Federal employee ? ) insurance plan.
If the WAC for Kaiser .....my Medicare plan ...is $143 a month and Kaiser only charges me $12 a month ( since June ) then Kaiser must want to keep me out of their ER really badly ...or AMRN has given them a huge rebate on their normal WAC ...or a combination of both
Just my non professional opinion
Kiwi
?
The $50 you paid over WAC was probably split between CostCo and GoodRx ...if both were involved .
The good part is that AMRN made a " wholesale " sale because without that coupon reducing your cost above WAC to only $50 ...you may not have bt Vascepa .
Theres a whole field of economics on price/ demand flexibility curves that the 3 players ( Costco / GoodRx/ AMRN are involved in here .
Re V card and insurance getting you to $9 a month
If the WAC is around $143 a month ....to get you to $9 a month AMRN is definitely rebating ( purchase discount ) some $ to you to get your purchase ...unless you have one outrageously good ( Federal employee ? ) insurance plan.
If the WAC for Kaiser .....my Medicare plan ...is $143 a month and Kaiser only charges me $12 a month ( since June ) then Kaiser must want to keep me out of their ER really badly ...or AMRN has given them a huge rebate on their normal WAC ...or a combination of both
Just my non professional opinion
Kiwi
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
